Verdence Capital Advisors LLC Makes New $571,000 Investment in Icon Plc $ICLR

Verdence Capital Advisors LLC bought a new stake in Icon Plc (NASDAQ:ICLR) during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 3,360 shares of the medical research company’s stock, valued at approximately $571,000.

A number of other hedge funds also recently added to or reduced their stakes in the stock. Polianta Ltd bought a new position in shares of Icon during the second quarter worth about $1,876,000. Maple Rock Capital Partners Inc. increased its holdings in shares of Icon by 257.8% in the 2nd quarter. Maple Rock Capital Partners Inc. now owns 1,199,600 shares of the medical research company’s stock worth $208,383,000 after acquiring an additional 864,300 shares during the period. Royal Bank of Canada lifted its position in Icon by 68.0% in the 1st quarter. Royal Bank of Canada now owns 153,728 shares of the medical research company’s stock valued at $17,011,000 after purchasing an additional 62,225 shares during the last quarter. Trinity Street Asset Management LLP lifted its position in Icon by 27.1% in the 2nd quarter. Trinity Street Asset Management LLP now owns 1,535,462 shares of the medical research company’s stock valued at $266,725,000 after purchasing an additional 327,314 shares during the last quarter. Finally, VELA Investment Management LLC boosted its stake in Icon by 511.4% during the 2nd quarter. VELA Investment Management LLC now owns 12,192 shares of the medical research company’s stock valued at $2,118,000 after purchasing an additional 10,198 shares during the period. 95.61% of the stock is currently owned by institutional investors.

Insider Activity at Icon

In other news, CAO Emer Lyons sold 272 shares of the company’s stock in a transaction that occurred on Friday, October 23rd. The shares were sold at an average price of $182.37, for a total value of $49,604.64. Following the completion of the sale, the chief accounting officer directly owned 990 shares of the company’s stock, valued at approximately $180,546.30. This represents a 21.55% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Ciaran Murray sold 2,677 shares of the stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $164.29, for a total transaction of $439,804.33. Following the completion of the transaction, the director owned 20,452 shares of the company’s stock, valued at $3,360,059.08. This trade represents a 11.57% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 23,068 shares of company stock worth $3,936,744 in the last three months. Insiders own 44.00% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have commented on ICLR. Weiss Ratings upgraded shares of Icon from a “sell (d)” rating to a “sell (d+)” rating in a research report on Wednesday. William Blair upgraded shares of Icon to a “strong-buy” rating in a research note on Thursday, July 30th. Truist Financial lifted their price target on Icon from $209.00 to $268.00 and gave the company a “buy” rating in a report on Thursday. UBS Group boosted their price objective on Icon from $195.00 to $236.00 and gave the stock a “neutral” rating in a research report on Thursday. Finally, BMO Capital Markets reissued an “outperform” rating and issued a $235.00 price objective on shares of Icon in a report on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, nine have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $211.53.

Key Headlines Impacting Icon

Here are the key news stories impacting Icon this week:

• Positive Sentiment: Analysts raise targets: TD Cowen lifted its price target from $197 to $254 and upgraded Icon to “buy,” implying approximately 17.9% upside from the referenced share price. Robert W. Baird raised its target from $210 to $249 and assigned an “outperform” rating, implying about 15.6% upside. TD Cowen analyst action Robert W. Baird analyst action
• Positive Sentiment: Strong bookings support future growth: Icon reported record net bookings of approximately $3.15 billion and indicated it expects mid-single-digit revenue growth in 2027, offering investors greater visibility into future demand. ICON 2027 revenue outlook
• Positive Sentiment: Capital returns expanded: Icon completed a $2.15 billion note issuance and redeemed 2.36 million shares during the third quarter. The company also announced expanded buybacks, which may support per-share results and signal management confidence. ICON debt issuance and share redemption
• Positive Sentiment: Guidance was raised: Despite softer quarterly results, Icon increased its 2026 outlook, providing a positive near-term catalyst for the stock. ICON third-quarter results and guidance
• Neutral Sentiment: Debt restructuring: Icon restructured debt while expanding buybacks and extending option plans. The financing supports capital allocation but increases the importance of managing leverage and interest costs. ICON debt restructuring announcement
• Negative Sentiment: Quarterly fundamentals were mixed: Third-quarter non-GAAP earnings and revenue declined year over year, although results exceeded expectations. The earnings decline and lower revenue remain risks if they persist. ICON third-quarter earnings release
• Negative Sentiment: Valuation concerns: One analysis argued that ICLR could be roughly 15% overvalued following its record wins and buyback announcement, creating downside risk after the stock’s strong advance toward its 52-week high. ICON valuation analysis

Icon Price Performance

Shares of NASDAQ ICLR opened at $215.48 on Friday. The stock has a market cap of $16.50 billion, a P/E ratio of 37.09, a P/E/G ratio of 13.65 and a beta of 1.24. The firm’s 50-day simple moving average is $171.22 and its 200 day simple moving average is $146.36. Icon Plc has a fifty-two week low of $66.57 and a fifty-two week high of $219.04. The company has a quick ratio of 0.95, a current ratio of 1.32 and a debt-to-equity ratio of 0.37.

Icon (NASDAQ:ICLR) last announced its earnings results on Tuesday, October 27th. The medical research company reported $2.66 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.62 by $0.04. The firm had revenue of $2.02 billion during the quarter, compared to analyst estimates of $2.01 billion. Icon had a net margin of 5.45% and a return on equity of 7.73%. Icon’s revenue was down .9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $3.31 EPS. Equities analysts expect that Icon Plc will post 9.68 EPS for the current year.

Icon Company Profile

ICON plc is a global contract research organization that provides outsourced development services to pharmaceutical, biotechnology and medical device companies. The company supports clinical research programs from early development through late-stage trials, regulatory submission and post-marketing activities.

Its services include clinical trial management, medical and regulatory consulting, biostatistics, data management, pharmacovigilance, laboratory services and real-world evidence solutions.